SG11201909229SA - Crystalline forms of (s)-afoxolaner - Google Patents
Crystalline forms of (s)-afoxolanerInfo
- Publication number
- SG11201909229SA SG11201909229SA SG11201909229SA SG11201909229SA SG 11201909229S A SG11201909229S A SG 11201909229SA SG 11201909229S A SG11201909229S A SG 11201909229SA SG 11201909229S A SG11201909229S A SG 11201909229SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- crystalline forms
- pct
- duluth
- chemin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Secondary Cells (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
WO 18/187 6 23 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT omit IIl °nolo mono mil (10) International Publication Number WO 2018/187623 Al (51) International Patent Classification: CO7D 261/04 (2006.01) A61P 33/00 (2006.01) A61K 31/42 (2006.01) (21) International Application Number: PCT/US2018/026328 (22) International Filing Date: 05 April 2018 (05.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/482,175 05 April 2017 (05.04.2017) US (71) Applicant: MERIAL, INC. [US/US]; 3239 Satellite Blvd., Duluth, GA 30096 (US). (72) Inventors: GORTER DE VRIES, Roelof, Johannes; 50 Avenue Marcel Merieux, 69290 St. Genis Les 011ieres (FR). BAILLON, Bruno; 9 Chemin De Pierre Grosse, 05300 Le Poet (FR). LAFONT, Sylvaine; 9 Rue Des Romarines, Lieu Dit Les Saiettes, 04160 Chateau-amoux (FR). GAY DE SAINT MICHEL, Myriam; 1 Chemin Du Pra De L'intra, 04310 Peyruis (FR). KOZLOVIC, Stephane; 22 Rue Du Bosquet, 04200 Sisteron (FR). (74) Agent: JARECKI-BLACK, Judy; 3239 Satelite Blvd., Duluth, GA 30096 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: CRYSTALLINE FORMS OF (S)-AFOXOLANER CI CF 3 CF 3 (Ia) (57) : The present invention provides crystalline forms of compound of formula (la) and processes of making the crystalline forms. Also provided are compositions comprising the crystalline forms and crystalline forms for treating or preventing parasitic in- fections in an animal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482175P | 2017-04-05 | 2017-04-05 | |
| PCT/US2018/026328 WO2018187623A1 (en) | 2017-04-05 | 2018-04-05 | Crystalline forms of (s)-afoxolaner |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909229SA true SG11201909229SA (en) | 2019-11-28 |
Family
ID=62092252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909229S SG11201909229SA (en) | 2017-04-05 | 2018-04-05 | Crystalline forms of (s)-afoxolaner |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10662163B2 (en) |
| EP (1) | EP3606911A1 (en) |
| JP (1) | JP7222909B2 (en) |
| KR (1) | KR102612648B1 (en) |
| CN (1) | CN111032634A (en) |
| AR (1) | AR111412A1 (en) |
| AU (1) | AU2018250304B2 (en) |
| BR (1) | BR112019021072A2 (en) |
| CA (1) | CA3059114A1 (en) |
| CL (1) | CL2019002840A1 (en) |
| CO (1) | CO2019011980A2 (en) |
| EA (1) | EA201992360A1 (en) |
| IL (1) | IL269792B (en) |
| MD (1) | MD20190080A2 (en) |
| MX (1) | MX2019011931A (en) |
| MY (1) | MY188420A (en) |
| PH (1) | PH12019502277A1 (en) |
| SG (1) | SG11201909229SA (en) |
| TW (1) | TWI782976B (en) |
| UA (1) | UA125727C2 (en) |
| UY (1) | UY37665A (en) |
| WO (1) | WO2018187623A1 (en) |
| ZA (1) | ZA201906464B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018250304B2 (en) * | 2017-04-05 | 2022-03-03 | Boehringer lngelheim Vetmedica GMBH | Crystalline forms of (S)-afoxolaner |
| WO2021254445A1 (en) * | 2020-06-19 | 2021-12-23 | 东莞市东阳光仿制药研发有限公司 | Crystal form of gaba inhibitor and preparation method therefor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI412322B (en) | 2005-12-30 | 2013-10-21 | Du Pont | Isoxazolines for controlling invertebrate pests |
| TWI430995B (en) * | 2007-06-26 | 2014-03-21 | Du Pont | Naphthalene isoxazoline invertebrate pest control agents |
| TWI649303B (en) * | 2007-08-17 | 2019-02-01 | 杜邦股份有限公司 | Compound and method for preparing 4-acetyl-n-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide |
| DK2576523T3 (en) * | 2010-05-27 | 2016-04-18 | Du Pont | A crystalline form of 4- [5- [3-chloro-5- (trifluoromethyl) phenyl] -4,5-dihydro-5- (trifluoromethyl) -3-isoxazolyl] -N- [2-oxo-2 - [( 2,2,2-trifluoroethyl) amino] ethyl] - 1-naphthalenecarboxamide |
| BR122019001738B1 (en) * | 2011-09-12 | 2019-11-05 | Merial Inc | parasiticidal compositions comprising an isoxazoline active agent and uses thereof |
| WO2014090918A1 (en) * | 2012-12-13 | 2014-06-19 | Novartis Ag | Process for the enantiomeric enrichment of diaryloxazoline derivatives |
| JP2015028006A (en) * | 2013-06-27 | 2015-02-12 | 日産化学工業株式会社 | Crystalline polymorph of isoxazoline compound and method for producing the same |
| UY36570A (en) * | 2015-02-26 | 2016-10-31 | Merial Inc | INJECTABLE FORMULATIONS OF PROLONGED ACTION THAT INCLUDE AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES OF THE SAME |
| SG10201912724SA (en) * | 2015-04-08 | 2020-02-27 | Boehringer Ingelheim Animal Health Usa Inc | Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof |
| RS62755B1 (en) | 2016-04-06 | 2022-01-31 | Boehringer Ingelheim Animal Health Usa Inc | Process for the preparation of enantiomerically enriched isoxazoline compounds - crystalline toluene solvate of (s)-afoxolaner |
| AU2018250304B2 (en) * | 2017-04-05 | 2022-03-03 | Boehringer lngelheim Vetmedica GMBH | Crystalline forms of (S)-afoxolaner |
-
2018
- 2018-04-05 AU AU2018250304A patent/AU2018250304B2/en active Active
- 2018-04-05 SG SG11201909229S patent/SG11201909229SA/en unknown
- 2018-04-05 EA EA201992360A patent/EA201992360A1/en unknown
- 2018-04-05 UA UAA201910863A patent/UA125727C2/en unknown
- 2018-04-05 WO PCT/US2018/026328 patent/WO2018187623A1/en unknown
- 2018-04-05 EP EP18721541.3A patent/EP3606911A1/en active Pending
- 2018-04-05 JP JP2019554802A patent/JP7222909B2/en active Active
- 2018-04-05 MX MX2019011931A patent/MX2019011931A/en unknown
- 2018-04-05 BR BR112019021072-5A patent/BR112019021072A2/en active Search and Examination
- 2018-04-05 US US15/946,642 patent/US10662163B2/en active Active
- 2018-04-05 CA CA3059114A patent/CA3059114A1/en active Pending
- 2018-04-05 MY MYPI2019005850A patent/MY188420A/en unknown
- 2018-04-05 KR KR1020197032461A patent/KR102612648B1/en active IP Right Grant
- 2018-04-05 MD MDA20190080A patent/MD20190080A2/en unknown
- 2018-04-05 UY UY0001037665A patent/UY37665A/en unknown
- 2018-04-05 CN CN201880033276.6A patent/CN111032634A/en active Pending
- 2018-04-05 AR ARP180100859A patent/AR111412A1/en unknown
- 2018-04-09 TW TW107112164A patent/TWI782976B/en active
-
2019
- 2019-10-01 ZA ZA2019/06464A patent/ZA201906464B/en unknown
- 2019-10-02 PH PH12019502277A patent/PH12019502277A1/en unknown
- 2019-10-03 IL IL269792A patent/IL269792B/en unknown
- 2019-10-04 CL CL2019002840A patent/CL2019002840A1/en unknown
- 2019-10-28 CO CONC2019/0011980A patent/CO2019011980A2/en unknown
-
2020
- 2020-03-20 US US16/825,616 patent/US11130739B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| UY37665A (en) | 2018-10-31 |
| UA125727C2 (en) | 2022-05-25 |
| US10662163B2 (en) | 2020-05-26 |
| AU2018250304A1 (en) | 2019-10-31 |
| MD20190080A2 (en) | 2020-04-30 |
| WO2018187623A1 (en) | 2018-10-11 |
| JP7222909B2 (en) | 2023-02-15 |
| CN111032634A (en) | 2020-04-17 |
| US11130739B2 (en) | 2021-09-28 |
| US20200270219A1 (en) | 2020-08-27 |
| WO2018187623A8 (en) | 2019-10-24 |
| MY188420A (en) | 2021-12-08 |
| IL269792B (en) | 2022-04-01 |
| MX2019011931A (en) | 2020-01-13 |
| TW201841895A (en) | 2018-12-01 |
| CL2019002840A1 (en) | 2020-01-10 |
| KR102612648B1 (en) | 2023-12-11 |
| AU2018250304B2 (en) | 2022-03-03 |
| EA201992360A1 (en) | 2020-09-02 |
| ZA201906464B (en) | 2021-08-25 |
| JP2020513010A (en) | 2020-04-30 |
| IL269792A (en) | 2019-11-28 |
| KR20190136055A (en) | 2019-12-09 |
| CA3059114A1 (en) | 2018-10-11 |
| TWI782976B (en) | 2022-11-11 |
| CO2019011980A2 (en) | 2020-02-18 |
| EP3606911A1 (en) | 2020-02-12 |
| BR112019021072A2 (en) | 2020-05-12 |
| PH12019502277A1 (en) | 2020-09-14 |
| AR111412A1 (en) | 2019-07-10 |
| US20180354917A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900947RA (en) | Tlr7/8 antagonists and uses thereof | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201811706RA (en) | Process for the preparation of microcapsules | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201906464UA (en) | Csf1r-based chimeric proteins | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |